



AI-powered digital therapy assistant to monitor and treat cognitive impairment in older adults over the phone

Jen Flexman, PhD¹, Jessie Ng, MHSc¹, Corinna Serviente, PhD², Rayhnuma Ahmed¹, Paul A Campbell¹, Rebecca Vaughan Darwish, MEd, CCC-SLP¹, Susan Kane, MS, CCC-SLP¹, Erin Smith, MA, CCC-SLP¹, Michael Busa, PhD²

¹Moneta Health, Tampa, FL; ²University of Massachusetts Amherst, Amherst, MA
MassAITC AD/ADRD Focus Pilot Core



The Gap in Care for Cognitive Impairment

Cognitive impairment affects 32% of adults over 65, impacting approximately 250 million people globally^{1,2}. Cognitive rehabilitation is an effective behavioral intervention for dementia to preserve independence, delay institutional care and reduce caregiver burden³. However, access to rehabilitation is currently limited by the availability of skilled providers, which disproportionately affects underserved and rural settings.

Alzheimer's Disease

Parkinson's Disease

Traumatic Brain Injury

Stroke

Other Dementias

Epilepsy

Sleep Disorders

1 in 3

Adults over 65 have a diagnosable cognitive impairment

Transforming Care through AI and the Telephone

Access to practical and personalized support is a critical component to helping older adults with cognitive impairment to remain independent in daily life. Moneta's AI-powered program offers a scalable model for therapists to deliver cognitive rehabilitation using a digital therapy assistant, reaching individuals at home over the basic telephone.





Figure: Overview of Moneta's automated therapy delivery system. Patients speak with a therapist and interact with an AI-powered digital therapy assistant weekly as part of their cognitive rehabilitation therapy program. Licensed speech therapists program remotely monitor patient sessions with the digital therapy assistant to assess progress and adapt the program over time.

AI Development for Automated Therapy Delivery

The MassAITC a2 pilot project will result in AI algorithms to classify patient responses and speech biomarkers collected during automated sessions with Moneta's digital therapy assistant. The usability and scalability of these algorithms will be evaluated and optimized with 30 older adults living with cognitive impairment to achieving predictive accuracy of >80%. The project will improve the efficiency of therapists using the platform to reach more patients in need.



Hear more from Moneta's patients in a short video!



Moneta's Real World Clinical Results

Cognitive Function

↑18%

Patient cognitive function significantly improved on average by 18% ($p < 0.001$), compared to 13% for traditional outpatient therapy^{4,5}.

Quality of Life

↑11%

Patient reported quality of life also significantly improved on average by 11% ($p < 0.001$)⁶.

Retention

85%

85% of patients who started the Moneta program complete it, reflecting a high level of patient satisfaction.

AI Engagement

58 min

Moneta's patients engage with the digital therapy assistant for an average of 58 min per week, representing ~60% of therapy delivery.

Quality outcomes were analyzed for 75 patients who completed Moneta's program under Medicare (average age 73 ± 10 , average MoCA score 20 ± 5 ; 59% had MCI, 33% had dementia, 8% had another diagnosis).

References & Notes:
[1] Manley et al., JAMA Neurology, 2022;79(12):1242-1249.
[2] Leaving No One Behind In An Ageing World: World Social Report, United Nations, 2023.
[3] Kudlicka et al., Cognitive rehabilitation for people with mild to moderate dementia, Cochrane Database of Systematic Reviews, 2023.
[4] Compared to therapy outcomes data in the National Outcomes Measurement System of the American Speech-Language-Hearing Association for ages 50-89, cognitive communication disorder, outpatient setting, accessed January 17, 2025.
[5] Functional communication measure (FCM) for cognitive function assessed by the treating speech language pathologist.
[6] Quality of Life in Neurological Disorders (Neuro QoL).

a2 Pilot Project Funding through MassAITC:



National Institute on Aging
grant P30AG073107

Investors:

true Ventures



HEALTH2047
CAPITAL PARTNERS

